Search

American Manufacturing Surges to Four-Year High as Factory Activity Expands

The White House announced on April 22, 2026, that the Institute for Supply Management's key manufacturing index registered its third consecutive month of expansion at its highest reading since 2022. Major companies announced significant U.S. manufacturing investments including U.S. Steel restarting its Gary Tin Mill in Indiana (225 jobs), Apple committing $600 billion over four years, Nvidia pledging $500 billion for AI chip production, and Johnson & Johnson investing $55 billion in new U.S. manufacturing. Foreign pharmaceutical companies AstraZeneca ($50 billion), Bristol Myers Squibb ($40 billion), and GSK ($30 billion) also announced major U.S. manufacturing expansions.

Clatterbridge Cancer Centre NHS Foundation Trust Awards £140,250 Breyanzi CAR T-Cell Contract

The Clatterbridge Cancer Centre NHS Foundation Trust has awarded a £140,250 contract (excluding VAT) for Breyanzi CAR T-Cell therapy products to Bristol-Myers Squibb Pharmaceuticals Limited. The direct award, justified on single-supplier technical grounds and commissioned via NHS England, covers an estimated 2-day contract period from 28 April 2026. The contract was signed no earlier than 27 April 2026 and will be performed at the Liverpool (UKD72) contract location.

Bristol-Myers Squibb FDA Response to Thomas Hayes M.D

Bristol-Myers Squibb submitted a response to FDA on regulations.gov regarding Thomas Hayes M.D. The document is accessible via a PDF download link. No substantive content text is visible in the source.

Antibody Compositions with Antioxidants for Subcutaneous Delivery

The USPTO published patent application US20260097118A1 assigned to Bristol-Myers Squibb Company, covering pharmaceutical compositions comprising an antibody and at least two antioxidants formulated for subcutaneous delivery. The application includes claims for methods using an endoglycosidase hydrolase enzyme in the composition. Filing date was September 29, 2025.

Bristol-Myers Squibb Hemoglobinopathy Treatment Compounds

USPTO published patent application US20260098028A1 by Bristol-Myers Squibb Company covering compounds for treatment of hemoglobinopathies. The application includes claims for pharmaceutical compositions and methods of preventing or treating these blood disorders. The A1 publication followed a September 2025 filing date with European application number 19328416.

Treatment of Lung Cancer Using Anti-PD-1 Antibody Combination

The USPTO published Bristol-Myers Squibb Company's patent application (US20260092114A1) for a method of treating lung cancer using a combination of an anti-PD-1 antibody administered by infusion in under 60 minutes and optionally an anti-CTLA-4 antibody administered in under 90 minutes. The application was filed on September 29, 2025.

Cognitive-Impairment Diagnostics For Schizophrenia

USPTO published patent application US20260090758A1 by Bristol-Myers Squibb Company for a method of diagnosing cognitive impairment in schizophrenia patients using electrical brain activity measurements. The invention processes neural activity data from electrodes attached to a patient's head along with stimulation data to determine modulation depth for cognitive assessment.

USPTO Patent Grant: Tumor Treatment with Antibodies

The USPTO has granted patent US12582713B2 to Bristol-Myers Squibb Company for methods of treating tumors using pharmaceutical compositions containing anti-PD-1 or anti-PD-L1 antibodies, particularly for subcutaneous delivery. The patent also covers compositions that include an endoglycosidase hydrolase enzyme.

CD28/OX40 Bispecific Antibodies for Solid Organ Transplant Rejection Treatment

The USPTO published patent application US20260092113A1, filed by Bristol-Myers Squibb, covering methods for treating solid organ transplant rejection using CD28/OX40 bispecific antibodies. The application (No. 19237572) claims a multispecific binding protein with a VHH domain targeting CD28 and a VH/VL domain targeting OX40. Inventors include Rami Lissilaa, Benjamin Suratt, and Jessica Voss.